Indication
Bacterial pneumonia
Bacterial pneumonia is an acute lower respiratory tract infection characterized by bacterial invasion and subsequent inflammation of the pulmonary parenchyma and alveolar spaces. Read more about Bacterial pneumonia
764 drugs 226 manufacturers
Drugs that treat it
Common Bacterial pneumonia therapies.
MINOCYCLINE HCL
CLARITHROMYCIN
DOXYCYCLINE HYCLATE
DOXYCYCLINE MONOHYDRATE
MOXIFLOXACIN HCL
CIPROFLOXACIN HCL
DOXYCYCLINE HYCLATE
CIPROFLOXACIN HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonBacterial pneumonia is an acute lower respiratory tract infection characterized by bacterial invasion and subsequent inflammation of the pulmonary parenchyma and alveolar spaces.
It affects pediatric, adult, and geriatric populations across both community-acquired and hospital-acquired settings, with higher morbidity and mortality occurring in older adults, young children, and immunocompromised individuals.
Pathophysiologically, the host immune response to bacterial pathogens—most frequently organisms such as *Streptococcus pneumoniae*—triggers cytokine release, increased capillary permeability, and an influx of neutrophils, resulting in alveolar exudate accumulation and consolidation.
Clinically, this process manifests with systemic and localized features, including fever, rigors, dyspnea, pleuritic chest pain, hypoxemia, and a productive cough with purulent sputum.
- nih.gov
Bacterial pneumonia is an acute lower respiratory tract infection characterized by bacterial invasion and subsequent inflammation of the pulmonary parenchyma and alveolar spaces It affects pediatric, adult, and geriatric populations across both community-acquired and hospital-acquired settings, with higher morbidity and mortality occurring in older adults, young children, and immunocompromised individuals Clinically, this process manifests with systemic and localized features, including fever, r...
- researchgate.net
Bacterial pneumonia is an acute lower respiratory tract infection characterized by bacterial invasion and subsequent inflammation of the pulmonary parenchyma and alveolar spaces
- nih.gov
It affects pediatric, adult, and geriatric populations across both community-acquired and hospital-acquired settings, with higher morbidity and mortality occurring in older adults, young children, and immunocompromised individuals Pathophysiologically, the host immune response to bacterial pathogens—most frequently organisms such as *Streptococcus pneumoniae*—triggers cytokine release, increased capillary permeability, and an influx of neutrophils, resulting in alveolar exudate accumulation and ...
- nih.gov
Pathophysiologically, the host immune response to bacterial pathogens—most frequently organisms such as *Streptococcus pneumoniae*—triggers cytokine release, increased capillary permeability, and an influx of neutrophils, resulting in alveolar exudate accumulation and consolidation
- nih.gov
Pathophysiologically, the host immune response to bacterial pathogens—most frequently organisms such as *Streptococcus pneumoniae*—triggers cytokine release, increased capillary permeability, and an influx of neutrophils, resulting in alveolar exudate accumulation and consolidation
- cdc.gov
Clinically, this process manifests with systemic and localized features, including fever, rigors, dyspnea, pleuritic chest pain, hypoxemia, and a productive cough with purulent sputum
Personalize your experience
Follow Bacterial pneumonia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.